Hepatitis C elimination program screens more than 45K individuals in first 2 years of launch.
Hepatitis/MASH
Latest News
Advertisement
CME Content
Advertisement
Triple drug regimen effectively cured patients with hepatitis C virus after they failed to respond to a combination of two oral direct-acting antivirals.
Elderly patients with hepatitis C are typically difficult to treat due to poor tolerability and suboptimal response to interferon-based regimens.
Top news of the week from Specialty Pharmacy Times.
Issues surrounding patents for curative drugs allow pharmaceutical companies to establish a market monopoly and charge astronomical prices.
An estimated 2.7 million Americans have hepatitis C, too many for specialists to be the sole provider of anti-HCV therapy.
Heplisav-B aims to boost a patient’s own immune response to fight off HBV.
Maviret is an 8-week treatment that combines 2 distinct antiviral agents.
Top news of the week from Specialty Pharmacy Times.
Officials with the FDA have announced the approval of glecaprevir and pibrentasvir (Mavyret, AbbVie Inc) for hepatitis C.
Mavyret approved for chronic hepatitis C virus genotypes 1-6 without cirrhosis or with mild cirrhosis.
Combination therapy cuts standard HCV treatment regimen from 12 weeks to 8 weeks.
HEV is reemerging as a zoonotic virus, with individuals becoming infected via pigs and pork products.
The label has been updated to include data from adults co-infected with hepatitis C virus and HIV-1.
Top articles of the week from Specialty Pharmacy Times.
Prequalification will allow countries to access generic sofosbuvir and an HIV self-test.
Approximately 325 million individuals are living with hepatitis worldwide.
There are now 8 FDA approved medications for HCV treatment, all of which bypass the use of interferon.
Those who battled hepatitis C recount their journey to spread awareness on World Hepatitis Day.
World Hepatitis Day highlights awareness and prevention initiatives in effort to improve access to curative treatments.
World Hepatitis Day brings awareness to the burden of hepatitis, which is a leading cause of death worldwide.
Sci-B-Vac is a third-generation vaccine against hepatitis B virus.
New treatments for inflammatory conditions, cancer, and HIV are on the horizon.Â
Top articles of the week from The American Journal of Pharmacy Benefits.
Transplanting organs from donors infected with hepatitis C found to be a viable option.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Emerging Biomarkers Open New Frontiers in Lung Cancer Therapy
2
Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC
3
Targeted α-Particle Radioligand Therapy Shows Promising Activity, Low Toxicity in SSTR2-Positive Neuroendocrine Tumors
4
Weekly Paclitaxel May Hold the Key to Pembrolizumab’s Success in Platinum-Resistance Ovarian Cancer
5
